Forum for Science, Industry and Business

Sponsored by:     3M 
Search our Site:

 

New Targeted Therapy for Treatment of Resistant Colorectal Cancer

23.07.2004


The drug cetuximab, a promising new targeted therapy better known as Erbitux, offers another option for patients who have colorectal cancer that resists standard chemotherapy treatment, according to an editorial written by two Mayo Clinic cancer researchers that will be published in the July 22 edition of the New England Journal of Medicine (NEJM).



The editorial is co-authored by Mayo Clinic’s Charles Erlichman, M.D., chair of the Department of Oncology and a specialist in the research and treatment of colorectal cancer, and Daniel Sargent, Ph.D., director of Cancer Center Statistics.

The editorial comments on a phase 2 randomized, three-year study that compared cetuximab combined with irinotecan, a standard chemotherapy regimen, to cetuximab alone in patients with metastatic colorectal cancer that is resistant to treatment with irinotecan. The study was led by David Cunningham, M.D., Royal Marsden Hospital, London and Surrey, in the United Kingdom, and its results will be published in the same issue of NEJM.


Dr. Erlichman notes that although the study indicated the benefits of cetuximab were modest in terms of stopping the cancer, patients’ response to the drug, and survival, it is nonetheless a step forward in the treatment of colorectal cancer that has spread to other parts of the body.

"Cetuximab combined with irinotecan offers patients with metastatic colorectal cancer another treatment option after failing treatment with irinotecan," he says.

About 150,000 people in the U.S. will be diagnosed with colorectal cancer this year, and more than 57,000 will die from it. Colorectal cancer is the second most common cancer in this country, accounting for about 10 percent of annual cancer deaths.

Irinotecan is a chemotherapy drug that is used alone or combined with two other chemotherapy drugs, fluorouracil and leucovorin, for treatment of patients with colorectal cancer. Oxaliplatin is another approved chemotherapy regimen that can be used in combination with fluorouracil and leucovorin as first-line treatment for colorectal cancer, or in patients who have failed irinotecan.

Cetuximab belongs to a new class of cancer drugs called targeted therapies, so named because the drugs go after the source of the cancer and leave healthy cells alone. Cetuximab’s purpose is to disable the epidermal growth factor receptor (EGFR), and thereby prevent cancer cell growth and decrease the ability of cancer cells to overcome the killing effect of chemotherapy.

In laboratory studies, cetuximab had been shown to enhance irinotecan’s antitumor abilities. The study to be reported in NEJM intended to determine whether adding cetuximab to irinotecan can resensitize tumors that are resistant to irinotecan. It found that cetuximab can decrease resistance to irinotecan.

However, Dr. Erlichman notes, there was insufficient evidence to prove that cetuximab improved patients’ survival. Additionally, he disagrees with the study author’s claim that cetuximab compares favorably to oxaliplatin therapy in patients whose colorectal cancer is resistant to irinotecan. He says the effectiveness of oxaliplatin therapy has been established in a large randomized phase 3 clinical study, while cetuximab has not been subjected to such validation.

He describes the results of this study as "the first step in defining the role of EGFR antibody targeted therapy in patients with colorectal cancer."

| newswise
Further information:
http://www.mayo.edu

More articles from Health and Medicine:

nachricht NTU scientists build new ultrasound device using 3-D printing technology
07.12.2016 | Nanyang Technological University

nachricht How to turn white fat brown
07.12.2016 | University of Pennsylvania School of Medicine

All articles from Health and Medicine >>>

The most recent press releases about innovation >>>

Die letzten 5 Focus-News des innovations-reports im Überblick:

Im Focus: Significantly more productivity in USP lasers

In recent years, lasers with ultrashort pulses (USP) down to the femtosecond range have become established on an industrial scale. They could advance some applications with the much-lauded “cold ablation” – if that meant they would then achieve more throughput. A new generation of process engineering that will address this issue in particular will be discussed at the “4th UKP Workshop – Ultrafast Laser Technology” in April 2017.

Even back in the 1990s, scientists were comparing materials processing with nanosecond, picosecond and femtosesecond pulses. The result was surprising:...

Im Focus: Shape matters when light meets atom

Mapping the interaction of a single atom with a single photon may inform design of quantum devices

Have you ever wondered how you see the world? Vision is about photons of light, which are packets of energy, interacting with the atoms or molecules in what...

Im Focus: Novel silicon etching technique crafts 3-D gradient refractive index micro-optics

A multi-institutional research collaboration has created a novel approach for fabricating three-dimensional micro-optics through the shape-defined formation of porous silicon (PSi), with broad impacts in integrated optoelectronics, imaging, and photovoltaics.

Working with colleagues at Stanford and The Dow Chemical Company, researchers at the University of Illinois at Urbana-Champaign fabricated 3-D birefringent...

Im Focus: Quantum Particles Form Droplets

In experiments with magnetic atoms conducted at extremely low temperatures, scientists have demonstrated a unique phase of matter: The atoms form a new type of quantum liquid or quantum droplet state. These so called quantum droplets may preserve their form in absence of external confinement because of quantum effects. The joint team of experimental physicists from Innsbruck and theoretical physicists from Hannover report on their findings in the journal Physical Review X.

“Our Quantum droplets are in the gas phase but they still drop like a rock,” explains experimental physicist Francesca Ferlaino when talking about the...

Im Focus: MADMAX: Max Planck Institute for Physics takes up axion research

The Max Planck Institute for Physics (MPP) is opening up a new research field. A workshop from November 21 - 22, 2016 will mark the start of activities for an innovative axion experiment. Axions are still only purely hypothetical particles. Their detection could solve two fundamental problems in particle physics: What dark matter consists of and why it has not yet been possible to directly observe a CP violation for the strong interaction.

The “MADMAX” project is the MPP’s commitment to axion research. Axions are so far only a theoretical prediction and are difficult to detect: on the one hand,...

All Focus news of the innovation-report >>>

Anzeige

Anzeige

Event News

ICTM Conference 2017: Production technology for turbomachine manufacturing of the future

16.11.2016 | Event News

Innovation Day Laser Technology – Laser Additive Manufacturing

01.11.2016 | Event News

#IC2S2: When Social Science meets Computer Science - GESIS will host the IC2S2 conference 2017

14.10.2016 | Event News

 
Latest News

NTU scientists build new ultrasound device using 3-D printing technology

07.12.2016 | Health and Medicine

The balancing act: An enzyme that links endocytosis to membrane recycling

07.12.2016 | Life Sciences

How to turn white fat brown

07.12.2016 | Health and Medicine

VideoLinks
B2B-VideoLinks
More VideoLinks >>>